JPRN-UMIN000015098已完成2 期
Phase II study of S-1+CPT-11+Bevacizumab as second-line therapy in metastatic colorectal cancer which has prior therapy of S-1+L-OHP+Bevacizumab - Phase II study of IRIS+BV as second-line therapy in metastatic colorectal cancer which has prior therapy of SOX + BV
Gunma University Graduate School0 个研究点目标入组 40 人开始时间: 2014年9月9日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. History of serious drug hypersensitivity 2. Pregnant, lactating or women of child-bearing potential. Men who want get partner pregnant. 3. Active infections 4. 4. Serious complications 5. Peptic ulcers 6. Over grade 2 diarrhea 7. Massive pleural effusion or ascites 8. Mechanical bowel obstruction 9. Symptomatic peritoneum dissemination 10. Brain metastasis 11. Current or previous (within the last 6 months) history of GI perforation 12. Hemoptysis 13. Previous history of thromboembolism, cerebral infarction, pulmonary infarction, interstitial pneumonia 14. Evidence of bleeding diathesis or coagulopathy 15. Ongoing treatment with anticoagulant or aspirin (> 325mg/day) 16. Administering transfusion within 14 days 17. Other active malignancies 18. Administration contraindication of 5-FU(Capecitabine, TS-1) Oxaliplatin, CPT-11 and Bevacizumab 19. Any other cases who are regarded as inadequate for study enrollment by the investigator
研究者
相似试验
已完成
2 期
Phase II study of S-1 plus Bevacizumab combination chemotherapy for patients with non-small-cell lung cancer.lung cancerJPRN-UMIN000004677Shinshu University thoracic surgery55
已完成
2 期
Phase II study of TS-1, CPT-11 and Bevacizumab combination chemotherapy in patients with metastatic colon cancerMetastatic colorectal cancerJPRN-UMIN000007072Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group40
已完成
2 期
Phase II study of S-1, leucovorin plus bevacizumab in refractory colorectal cancerColorectal cancerJPRN-UMIN000009083Aichi Cancer Center Hospital, Department of Clinical Oncology30
已完成
2 期
Phase II study of TS-1+Irinotecan+Bevacizumab as second-line treatment in patients with metastatic colorectal cancer refractory to fluoronated pyrimidine, oxaliplatin, and cetuximab therapyMetastatic colorectal cancerJPRN-UMIN000010319Japan Clinical Cancer Research Organization70
已完成
2 期
Phase II study of Bevacizumab with SOX (S-1 plus L-OHP) as second-line therapy in metastatic colorectal cancerMetastatic colorectal cancerJPRN-UMIN000005199Tsuchiura kyodo general hospital33